Table 1.
Demographic and baseline clinical characteristics. If not otherwise stated, entries are mean and 95% CI.
| Heparan sulfate | GAGPS | |
|---|---|---|
| Demographic characteristics | ||
| Gender (n-%): | ||
| males | 30 (41.7%) | 21 (43.8%) |
| females | 28 (58.3%) | 27 (56.3%) |
| Age (years) | 41.9 (37.4 to 46.5) | 38.3 (34.0 to 42.6) |
| Weight (kg) | 70.9 (67.5 to 74.4) | 69.8 (66.7 to 72.9) |
| Height (cm) | 172.4 (170.0 to 174.8) | 172.5 (169.7 to 175.3) |
| BMI (cm/m2) | 23.8 (22.9 to 24.7) | 23.4 (22.6 to 24.3) |
|
| ||
| Baseline subjective symptoms and objective signs | ||
| Pain at rest | 1.3 (1.1 to 1.4) | 1.2 (1.0 to 1.3) |
| Pain at movement | 2.3 (2.1 to 2.4) | 2.3 (2.2 to 2.5) |
| Functional disability | 2.1 (2.0 to 2.3) | 2.3 (2.1 to 2.5) |
| Oedema | 2.4 (2.2 to 2.6) | 2.5 (2.3 to 2.6) |
| Colour of the lesion | 3.0 (3.0 to 3.0) | 3.0 (2.9 to 3.0) |
| Total score | 11.1 (10.6 to 11.6) | 11.2 (10.8 to 11.7) |
|
| ||
| Size of haematomas/extravasation at baseline | ||
| Minimum diameter (cm) | 5.7 (5.1 to 6.3) | 6.0 (5.4 to 6.7) |
| Maximum diameter (cm) | 8.8 (8.1 to 9.6) | 9.0 (8.1 to 9.9) |
| Min*Max diameter (cm2) | 53.9 (44.4 to 63.4) | 60.0 (44.0 to 76.1) |